Tag: GlobeNewswire

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO^® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.¹

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO^® offers a first-in-class mechanism that targets the underlying drivers of this debilitating condition, and we are proud to bring it to patients in Brazil. This approval reflects the strength of our partnership with Incyte and our shared commitment to ensuring that patients in Brazil have access to innovative therapies that can make a meaningful difference in their lives,” said Samira Sakhia, President and CEO of Knight Therapeutics.

In September 2021, Knight and Incyte (NASDAQ: INCY) had entered into an exclusive supply and distribution agreement for MINJUVI^® (tafasitamab) and PEMAZYRE^® (pemigatinib) in Latin America. In August 2025, Knight expanded its existing relationship with Incyte, to add exclusive rights to distribute ZYNYZ^® (retifanlimab) and NIKTIMVO^® (axatilimab) in Latin America. Under the terms of the amended agreement, Incyte is responsible for the development, manufacture and supply of such products to Knight, and Knight is responsible for seeking the necessary regulatory approvals and commercializing such products in Latin America.

About NIKTIMVO^®

NIKTIMVO^® (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).²

In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

NIKTIMVO^®, MINJUVI^®, PEMAZYRE^® and ZYNYZ^® are trademarks of Incyte. All other trademarks are the property of their respective owners.

About cGVHD

Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor’s immune cells attack the recipient’s tissues, often occurring during the first-year post-transplant.³ Chronic GVHD involves features of autoimmunity and immunodeficiency, multiple organs (such as the skin, liver, lungs, and gastrointestinal tract), irreversible fibrotic manifestations, and systemic toxicities complicated by the use of immunosuppressants which all contribute to devastating health consequences such as mortality, morbidity, and decreased quality of life in patients.⁴ There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.⁵ Chronic GVHD is the most common late complication after allogeneic hematopoietic cell transplantation affecting 30%-70% of recipients, globally.⁴ Based on a recent analysis by the Brazilian National hematopoietic stem cell transplantation (HSCT) Registry, in collaboration with Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO), Center for International Blood and Marrow Transplant Research (CIBMTR), and Hematopoietic Cell Transplantation Brazilian Registry (HCTBR), the 2-year cumulative incidence cGVHD was determined to be 29.5%.⁶

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on October 5, 2026.
2. Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Highlights of prescribing information / full prescribing information. Revised August 2024. Accessed June 10, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdf
3. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215. doi:10.1016/j.bbmt.2007.07.001
4. Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2023;41(10):1864-1875. doi:10.1200/JCO.22.00958
5. Associação Brasileira de Transplante de Órgãos. (2024). Registro Brasileiro de Transplantes (RBT): Dados numéricos da doação de órgãos e transplantes realizados por estado e instituição no período: janeiro/setembro 2024 (Ano XXV, nº 3) [Report]. Retrieved May 26, 2026, from https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdf
6. Simione, Anderson Joao, et al. “Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators.” Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT), vol. 6, no. 1, 2025, pp. 1–13. doi: 10.46765/2675-374X.2025V6N1P270.

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T: 514.484.4483
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO^® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.¹

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO^® offers a first-in-class mechanism that targets the underlying drivers of this debilitating condition, and we are proud to bring it to patients in Brazil. This approval reflects the strength of our partnership with Incyte and our shared commitment to ensuring that patients in Brazil have access to innovative therapies that can make a meaningful difference in their lives,” said Samira Sakhia, President and CEO of Knight Therapeutics.

In September 2021, Knight and Incyte (NASDAQ: INCY) had entered into an exclusive supply and distribution agreement for MINJUVI^® (tafasitamab) and PEMAZYRE^® (pemigatinib) in Latin America. In August 2025, Knight expanded its existing relationship with Incyte, to add exclusive rights to distribute ZYNYZ^® (retifanlimab) and NIKTIMVO^® (axatilimab) in Latin America. Under the terms of the amended agreement, Incyte is responsible for the development, manufacture and supply of such products to Knight, and Knight is responsible for seeking the necessary regulatory approvals and commercializing such products in Latin America.

About NIKTIMVO^®

NIKTIMVO^® (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).²

In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

NIKTIMVO^®, MINJUVI^®, PEMAZYRE^® and ZYNYZ^® are trademarks of Incyte. All other trademarks are the property of their respective owners.

About cGVHD

Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor’s immune cells attack the recipient’s tissues, often occurring during the first-year post-transplant.³ Chronic GVHD involves features of autoimmunity and immunodeficiency, multiple organs (such as the skin, liver, lungs, and gastrointestinal tract), irreversible fibrotic manifestations, and systemic toxicities complicated by the use of immunosuppressants which all contribute to devastating health consequences such as mortality, morbidity, and decreased quality of life in patients.⁴ There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.⁵ Chronic GVHD is the most common late complication after allogeneic hematopoietic cell transplantation affecting 30%-70% of recipients, globally.⁴ Based on a recent analysis by the Brazilian National hematopoietic stem cell transplantation (HSCT) Registry, in collaboration with Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO), Center for International Blood and Marrow Transplant Research (CIBMTR), and Hematopoietic Cell Transplantation Brazilian Registry (HCTBR), the 2-year cumulative incidence cGVHD was determined to be 29.5%.⁶

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on October 5, 2026.
2. Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Highlights of prescribing information / full prescribing information. Revised August 2024. Accessed June 10, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdf
3. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215. doi:10.1016/j.bbmt.2007.07.001
4. Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2023;41(10):1864-1875. doi:10.1200/JCO.22.00958
5. Associação Brasileira de Transplante de Órgãos. (2024). Registro Brasileiro de Transplantes (RBT): Dados numéricos da doação de órgãos e transplantes realizados por estado e instituição no período: janeiro/setembro 2024 (Ano XXV, nº 3) [Report]. Retrieved May 26, 2026, from https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdf
6. Simione, Anderson Joao, et al. “Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators.” Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT), vol. 6, no. 1, 2025, pp. 1–13. doi: 10.46765/2675-374X.2025V6N1P270.

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T: 514.484.4483
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO^® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.¹

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO^® offers a first-in-class mechanism that targets the underlying drivers of this debilitating condition, and we are proud to bring it to patients in Brazil. This approval reflects the strength of our partnership with Incyte and our shared commitment to ensuring that patients in Brazil have access to innovative therapies that can make a meaningful difference in their lives,” said Samira Sakhia, President and CEO of Knight Therapeutics.

In September 2021, Knight and Incyte (NASDAQ: INCY) had entered into an exclusive supply and distribution agreement for MINJUVI^® (tafasitamab) and PEMAZYRE^® (pemigatinib) in Latin America. In August 2025, Knight expanded its existing relationship with Incyte, to add exclusive rights to distribute ZYNYZ^® (retifanlimab) and NIKTIMVO^® (axatilimab) in Latin America. Under the terms of the amended agreement, Incyte is responsible for the development, manufacture and supply of such products to Knight, and Knight is responsible for seeking the necessary regulatory approvals and commercializing such products in Latin America.

About NIKTIMVO^®

NIKTIMVO^® (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).²

In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

NIKTIMVO^®, MINJUVI^®, PEMAZYRE^® and ZYNYZ^® are trademarks of Incyte. All other trademarks are the property of their respective owners.

About cGVHD

Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor’s immune cells attack the recipient’s tissues, often occurring during the first-year post-transplant.³ Chronic GVHD involves features of autoimmunity and immunodeficiency, multiple organs (such as the skin, liver, lungs, and gastrointestinal tract), irreversible fibrotic manifestations, and systemic toxicities complicated by the use of immunosuppressants which all contribute to devastating health consequences such as mortality, morbidity, and decreased quality of life in patients.⁴ There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.⁵ Chronic GVHD is the most common late complication after allogeneic hematopoietic cell transplantation affecting 30%-70% of recipients, globally.⁴ Based on a recent analysis by the Brazilian National hematopoietic stem cell transplantation (HSCT) Registry, in collaboration with Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO), Center for International Blood and Marrow Transplant Research (CIBMTR), and Hematopoietic Cell Transplantation Brazilian Registry (HCTBR), the 2-year cumulative incidence cGVHD was determined to be 29.5%.⁶

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on October 5, 2026.
2. Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Highlights of prescribing information / full prescribing information. Revised August 2024. Accessed June 10, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdf
3. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215. doi:10.1016/j.bbmt.2007.07.001
4. Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2023;41(10):1864-1875. doi:10.1200/JCO.22.00958
5. Associação Brasileira de Transplante de Órgãos. (2024). Registro Brasileiro de Transplantes (RBT): Dados numéricos da doação de órgãos e transplantes realizados por estado e instituição no período: janeiro/setembro 2024 (Ano XXV, nº 3) [Report]. Retrieved May 26, 2026, from https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdf
6. Simione, Anderson Joao, et al. “Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators.” Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT), vol. 6, no. 1, 2025, pp. 1–13. doi: 10.46765/2675-374X.2025V6N1P270.

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia		Arvind Utchanah
President & Chief Executive Officer		Chief Financial Officer
T: 514.484.4483		T: 514.484.4483
Email: IR@knighttx.com		Email: IR@knighttx.com
Website: www.knighttx.com		Website: www.knighttx.com

ParaZero’s DefendAir paired with ThirdEye’s new armored-vehicle detection layer, following the companies’ September framework announcement to combine detection and physical interception

KFAR SABA, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero” or the “Company”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry,
today announced that its DefendAir net-based interception technology is being paired with ThirdEye Systems Ltd.’s (TASE: THES) newly unveiled Iron Web detection product as part of an integrated counter-UAS architecture for armored vehicles.

ThirdEye unveiled Iron Web at ADEX 2026 in Baku. Iron Web is designed to give armored combat vehicles a perimeter drone-detection layer and to complement ThirdEye’s Argus Shield system.

Under the architecture, ThirdEye’s electro-optical and AI-driven detection is intended to find and classify an approaching drone, and DefendAir is intended to provide the last physical layer: a controlled, non-explosive net launch designed to stop the drone before it reaches the vehicle. The same concept is intended to be applicable to critical infrastructure and other sensitive sites.

The announcement builds on the non-binding memorandum of understanding the companies disclosed on September 15, 2026. That MOU set a framework to explore the development, integration and commercialization of a 360° detect-to-defeat solution.

“An armored vehicle needs more than an alert. It needs a proven way to stop the threat,” said Ariel Alon, Chief Executive Officer of ParaZero. “Iron Web brings together two leading technologies: ThirdEye’s detection capabilities and ParaZero’s DefendAir net interceptors. Together, they connect detection with physical interception, setting a new standard in C-UAS protection for armored vehicles.”

DefendAir is designed for integration across personal, mobile, autonomous and fixed-site counter-UAS configurations. ParaZero and ThirdEye intend to continue the integration and commercialization work described in their September MOU.

The DefendAir product family and ThirdEye’s Iron Web will be showcased at ParaZero’s booth at the AUSA Annual Meeting in Washington, D.C., October 12–14, within the SIBAT (Israeli Ministry of Defense) National Defense Pavilion, Booth #739.

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.

Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.

The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.

For more information, visit ParaZero https://parazero.com/

About ThirdEye Systems

Founded in 2010, ThirdEye Systems is a pioneering developer of advanced AI-based solutions for optical systems and autonomous platforms, with a strong focus on defense and security applications.

The company specializes in edge AI applications and provides innovative real-time image processing technology, enabling tracking and control under challenging operational conditions. ThirdEye Systems’ solutions deliver rapid and high-quality responses to evolving threats, including protection against UAVs and drones.

The company’s products are designed to be reliable, mobile, and operational 24/7, providing an optimal solution for operational units in the field.

ThirdEye Systems’ solutions set a new standard in integrating artificial intelligence with defense and security systems, advancing the capabilities of the field.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the proposed development and integration of DefendAir with ThirdEye’s Iron Web; the parties’ ability to enter into definitive agreements and continue their technical and commercialization activities; the anticipated capabilities, performance, development, testing and potential applications of the proposed integrated architecture; the potential benefits of the parties’ collaboration; the planned presentation of the technologies at the AUSA Annual Meeting; and the potential adoption or commercialization of the proposed solution for armored vehicles, critical infrastructure and other sensitive sites. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

ParaZero’s DefendAir paired with ThirdEye’s new armored-vehicle detection layer, following the companies’ September framework announcement to combine detection and physical interception

KFAR SABA, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero” or the “Company”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry,
today announced that its DefendAir net-based interception technology is being paired with ThirdEye Systems Ltd.’s (TASE: THES) newly unveiled Iron Web detection product as part of an integrated counter-UAS architecture for armored vehicles.

ThirdEye unveiled Iron Web at ADEX 2026 in Baku. Iron Web is designed to give armored combat vehicles a perimeter drone-detection layer and to complement ThirdEye’s Argus Shield system.

Under the architecture, ThirdEye’s electro-optical and AI-driven detection is intended to find and classify an approaching drone, and DefendAir is intended to provide the last physical layer: a controlled, non-explosive net launch designed to stop the drone before it reaches the vehicle. The same concept is intended to be applicable to critical infrastructure and other sensitive sites.

The announcement builds on the non-binding memorandum of understanding the companies disclosed on September 15, 2026. That MOU set a framework to explore the development, integration and commercialization of a 360° detect-to-defeat solution.

“An armored vehicle needs more than an alert. It needs a proven way to stop the threat,” said Ariel Alon, Chief Executive Officer of ParaZero. “Iron Web brings together two leading technologies: ThirdEye’s detection capabilities and ParaZero’s DefendAir net interceptors. Together, they connect detection with physical interception, setting a new standard in C-UAS protection for armored vehicles.”

DefendAir is designed for integration across personal, mobile, autonomous and fixed-site counter-UAS configurations. ParaZero and ThirdEye intend to continue the integration and commercialization work described in their September MOU.

The DefendAir product family and ThirdEye’s Iron Web will be showcased at ParaZero’s booth at the AUSA Annual Meeting in Washington, D.C., October 12–14, within the SIBAT (Israeli Ministry of Defense) National Defense Pavilion, Booth #739.

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.

Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.

The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.

For more information, visit ParaZero https://parazero.com/

About ThirdEye Systems

Founded in 2010, ThirdEye Systems is a pioneering developer of advanced AI-based solutions for optical systems and autonomous platforms, with a strong focus on defense and security applications.

The company specializes in edge AI applications and provides innovative real-time image processing technology, enabling tracking and control under challenging operational conditions. ThirdEye Systems’ solutions deliver rapid and high-quality responses to evolving threats, including protection against UAVs and drones.

The company’s products are designed to be reliable, mobile, and operational 24/7, providing an optimal solution for operational units in the field.

ThirdEye Systems’ solutions set a new standard in integrating artificial intelligence with defense and security systems, advancing the capabilities of the field.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the proposed development and integration of DefendAir with ThirdEye’s Iron Web; the parties’ ability to enter into definitive agreements and continue their technical and commercialization activities; the anticipated capabilities, performance, development, testing and potential applications of the proposed integrated architecture; the potential benefits of the parties’ collaboration; the planned presentation of the technologies at the AUSA Annual Meeting; and the potential adoption or commercialization of the proposed solution for armored vehicles, critical infrastructure and other sensitive sites. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

ParaZero’s DefendAir paired with ThirdEye’s new armored-vehicle detection layer, following the companies’ September framework announcement to combine detection and physical interception

KFAR SABA, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero” or the “Company”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry,
today announced that its DefendAir net-based interception technology is being paired with ThirdEye Systems Ltd.’s (TASE: THES) newly unveiled Iron Web detection product as part of an integrated counter-UAS architecture for armored vehicles.

ThirdEye unveiled Iron Web at ADEX 2026 in Baku. Iron Web is designed to give armored combat vehicles a perimeter drone-detection layer and to complement ThirdEye’s Argus Shield system.

Under the architecture, ThirdEye’s electro-optical and AI-driven detection is intended to find and classify an approaching drone, and DefendAir is intended to provide the last physical layer: a controlled, non-explosive net launch designed to stop the drone before it reaches the vehicle. The same concept is intended to be applicable to critical infrastructure and other sensitive sites.

The announcement builds on the non-binding memorandum of understanding the companies disclosed on September 15, 2026. That MOU set a framework to explore the development, integration and commercialization of a 360° detect-to-defeat solution.

“An armored vehicle needs more than an alert. It needs a proven way to stop the threat,” said Ariel Alon, Chief Executive Officer of ParaZero. “Iron Web brings together two leading technologies: ThirdEye’s detection capabilities and ParaZero’s DefendAir net interceptors. Together, they connect detection with physical interception, setting a new standard in C-UAS protection for armored vehicles.”

DefendAir is designed for integration across personal, mobile, autonomous and fixed-site counter-UAS configurations. ParaZero and ThirdEye intend to continue the integration and commercialization work described in their September MOU.

The DefendAir product family and ThirdEye’s Iron Web will be showcased at ParaZero’s booth at the AUSA Annual Meeting in Washington, D.C., October 12–14, within the SIBAT (Israeli Ministry of Defense) National Defense Pavilion, Booth #739.

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.

Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.

The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.

For more information, visit ParaZero https://parazero.com/

About ThirdEye Systems

Founded in 2010, ThirdEye Systems is a pioneering developer of advanced AI-based solutions for optical systems and autonomous platforms, with a strong focus on defense and security applications.

The company specializes in edge AI applications and provides innovative real-time image processing technology, enabling tracking and control under challenging operational conditions. ThirdEye Systems’ solutions deliver rapid and high-quality responses to evolving threats, including protection against UAVs and drones.

The company’s products are designed to be reliable, mobile, and operational 24/7, providing an optimal solution for operational units in the field.

ThirdEye Systems’ solutions set a new standard in integrating artificial intelligence with defense and security systems, advancing the capabilities of the field.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the proposed development and integration of DefendAir with ThirdEye’s Iron Web; the parties’ ability to enter into definitive agreements and continue their technical and commercialization activities; the anticipated capabilities, performance, development, testing and potential applications of the proposed integrated architecture; the potential benefits of the parties’ collaboration; the planned presentation of the technologies at the AUSA Annual Meeting; and the potential adoption or commercialization of the proposed solution for armored vehicles, critical infrastructure and other sensitive sites. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

Fingrid Oyj’s Shareholders have on 5 October 2026 unanimously decided to elect Hannu Hautala as a member of the Board of Directors.

Hannu Hautala, M. Sc. (Engineering), Finnish citizen, has acted as a CEO at Luxmet Oy since September 2026. Earlier Hautala has acted as a CEO at Keliber Oy, as a CEO at Nordkalk Oy Ab, in different executive and senior positions at Outokumpu Oyj, in different executive positions at Elcoteq SE and Flextronics Holding Finland Oy and in different executive positions at Rautaruukki Oyj.

Hannu Hautala is independent from the company and its significant shareholders. Hautala has given his consent to his appointment.

After the election, the Board of Directors consist of five (5) members: Eeva-Liisa Virkkunen (Chair), Leena Mörttinen (deputy Chair), Jero Ahola, Hannu Hautala and Mika Lehtimäki. 

Contact information:
SVP, Legal Affairs and Sustainability, Marina Louhija
tel. +358 30 395 5289

About Fingrid Oyj

Fingrid is Finland’s transmission system operator. We secure reliable electricity for our customers and society, and are shaping the power system of the future. Our vision is clean, secure and the most competitive electricity system in Europe. 

Fingrid delivers. Responsibly.
www.fingrid.fi

Fingrid Oyj’s Shareholders have on 5 October 2026 unanimously decided to elect Hannu Hautala as a member of the Board of Directors.

Hannu Hautala, M. Sc. (Engineering), Finnish citizen, has acted as a CEO at Luxmet Oy since September 2026. Earlier Hautala has acted as a CEO at Keliber Oy, as a CEO at Nordkalk Oy Ab, in different executive and senior positions at Outokumpu Oyj, in different executive positions at Elcoteq SE and Flextronics Holding Finland Oy and in different executive positions at Rautaruukki Oyj.

Hannu Hautala is independent from the company and its significant shareholders. Hautala has given his consent to his appointment.

After the election, the Board of Directors consist of five (5) members: Eeva-Liisa Virkkunen (Chair), Leena Mörttinen (deputy Chair), Jero Ahola, Hannu Hautala and Mika Lehtimäki. 

Contact information:
SVP, Legal Affairs and Sustainability, Marina Louhija
tel. +358 30 395 5289

About Fingrid Oyj

Fingrid is Finland’s transmission system operator. We secure reliable electricity for our customers and society, and are shaping the power system of the future. Our vision is clean, secure and the most competitive electricity system in Europe. 

Fingrid delivers. Responsibly.
www.fingrid.fi

Fingrid Oyj’s Shareholders have on 5 October 2026 unanimously decided to elect Hannu Hautala as a member of the Board of Directors.

Hannu Hautala, M. Sc. (Engineering), Finnish citizen, has acted as a CEO at Luxmet Oy since September 2026. Earlier Hautala has acted as a CEO at Keliber Oy, as a CEO at Nordkalk Oy Ab, in different executive and senior positions at Outokumpu Oyj, in different executive positions at Elcoteq SE and Flextronics Holding Finland Oy and in different executive positions at Rautaruukki Oyj.

Hannu Hautala is independent from the company and its significant shareholders. Hautala has given his consent to his appointment.

After the election, the Board of Directors consist of five (5) members: Eeva-Liisa Virkkunen (Chair), Leena Mörttinen (deputy Chair), Jero Ahola, Hannu Hautala and Mika Lehtimäki. 

Contact information:
SVP, Legal Affairs and Sustainability, Marina Louhija
tel. +358 30 395 5289

About Fingrid Oyj

Fingrid is Finland’s transmission system operator. We secure reliable electricity for our customers and society, and are shaping the power system of the future. Our vision is clean, secure and the most competitive electricity system in Europe. 

Fingrid delivers. Responsibly.
www.fingrid.fi

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

• SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD

JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced completion of a Phase 1 study of SCY-770, a first-in-class, selective and direct AMP-activated protein kinase (AMPK) activator. The study was conducted to evaluate the safety and tolerability, as well as to characterize the pharmacokinetics of SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

“We continue to make strong progress toward initiating our Phase 2 study of SCY-770 in patients with ADPKD, and the additional pharmacokinetic and safety data generated in this Phase 1 study provide important insights to support dose selection,” said Todd Minga, M.D., SVP of Research and Development at SCYNEXIS. “We are encouraged by the favorable safety and tolerability profile observed across the doses studied, which supports continued clinical development of SCY-770. Patients living with ADPKD face a significant unmet medical need, as treatment options remain limited. We look forward to advancing this novel, highly selective oral direct AMPK activator, which has the potential to offer a differentiated therapeutic approach and provide meaningful clinical benefit for patients with this progressive disease.”

The Phase 1 study enrolled 25 healthy participants across three cohorts. In the initial cohort, participants received a single 500 mg dose of SCY-770 under fed and fasted conditions. Participants in the subsequent cohorts received SCY-770 at either 750 mg once daily or 500 mg twice daily, or placebo, for seven days. SCY-770 was well tolerated across all cohorts and demonstrated a safety profile consistent with prior clinical experience. Pharmacokinetic data from this and prior studies will inform dose selection for the Phase 2 trial in patients with ADPKD, which remains on track to initiate in the fourth quarter of 2026.

The safety and tolerability of SCY-770 has been well-characterized across multiple clinical trials in approximately 300 participants to date. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disease caused by mutations of the PKD1 or PKD2 genes which encode polycystin complex 1 (PC1) or polycystin complex 2 (PC2) proteins, critical for normal tubular epithelial cell function. Patients develop fluid-filled cysts in their kidneys that progressively impair kidney function with more than 50% reaching end-stage renal failure by the age of 60 requiring renal replacement therapies (e.g., dialysis or transplant). The U.S. prevalence of ADPKD is estimated to be 140,000 patients, with approximately 6,000 new cases diagnosed each year. ADPKD currently has only one approved therapy, Jynarque (tolvaptan), which achieved approximately $1.5 billion in U.S. sales in 2024 despite limited patient uptake due to safety, tolerability, and monitoring requirements.

About SCY-770

SCY-770 is a novel, highly selective, oral direct activator of adenosine monophosphate-activated protein kinase (AMPK) being developed as a potential disease-modifying therapy for autosomal dominant polycystic kidney disease (ADPKD), a progressive genetic disorder characterized by significant unmet medical need. By activating AMPK, SCY-770 targets multiple pathways implicated in disease progression, including mTOR and cAMP signaling, which are known to drive cyst growth and fluid secretion. In addition, AMPK activation is associated with reduction in inflammation and fibrosis while improving cellular metabolism, offering a differentiated, multi-mechanistic approach to address the underlying drivers of ADPKD. SCY-770 has been evaluated across multiple clinical trials in approximately 300 participants to date. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the anticipated initiation of the Phase 2 proof-of-concept study of SCY-770 in ADPKD patients in the fourth quarter of 2026; the use of population pharmacokinetic modeling to support Phase 2 dose selection; and the potential for SCY-770 to serve as a disease-modifying therapy for ADPKD. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products, including the risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study design on the anticipated timeline or at all. These and other risks are described more fully in SCYNEXIS’ filings with the Securities and Exchange Commission, including without limitation, the section titled “Risk Factors” in its most recent Annual Report on Form 10-K, and in other filings made with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com